<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01160731</url>
  </required_header>
  <id_info>
    <org_study_id>07-09 ICORG</org_study_id>
    <secondary_id>ICORG-07-09</secondary_id>
    <secondary_id>EUDRACT-2008-003634-21</secondary_id>
    <secondary_id>EU-21047</secondary_id>
    <nct_id>NCT01160731</nct_id>
  </id_info>
  <brief_title>Panobinostat, Etoposide, and Cisplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer</brief_title>
  <official_title>A Phase I Dose Finding Study of the Pan-DAC Inhibitor Panobinostat (LBH589) in Combination With Etoposide and Cisplatin in the First Line Treatment of Extensive-Stage Small Cell Lung Cancer - An ICORG In-House Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer Trials Ireland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cancer Trials Ireland</source>
  <brief_summary>
    <textblock>
      RATIONALE: Panobinostat may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy,&#xD;
      such as etoposide and cisplatin, work in different ways to stop the growth of tumor cells,&#xD;
      either by killing the cells or by stopping them from dividing. Giving panobinostat together&#xD;
      with etoposide and cisplatin may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of panobinostat when&#xD;
      given together with etoposide and cisplatin as first-line therapy in treating patients with&#xD;
      extensive-stage small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the maximum-tolerated dose, the recommended dose, and the activity of&#xD;
           panobinostat when given in combination with etoposide and cisplatin to patients with&#xD;
           extensive-stage small cell lung cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To estimate the time-to-progression, the duration of response, and disease stabilization&#xD;
           in these patients.&#xD;
&#xD;
        -  To estimate the overall survival of these patients.&#xD;
&#xD;
        -  To determine the pharmacokinetic profile of panobinostat in combination with etoposide&#xD;
           and cisplatin.&#xD;
&#xD;
        -  To assess the overall safety profile of panobinostat in these patients.&#xD;
&#xD;
        -  To determine the adverse events in these patients treated with this regimen.&#xD;
&#xD;
        -  To assess the quality of life of these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study of panobinostat.&#xD;
&#xD;
      Patients receive chemotherapy comprising cisplatin IV on day 1, etoposide IV on days 1-3, and&#xD;
      panobinostat IV over 30 minutes on days 1 and 8. Treatment repeats every 3 weeks for up to 6&#xD;
      courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Quality of life is assessed at baseline and then periodically during study treatment and&#xD;
      follow up, using questionnaire EQ-5D (Euro QoL).&#xD;
&#xD;
      Blood samples may be collected at baseline and periodically during and after study treatment&#xD;
      for pharmacokinetic assessment and biomarker translational studies.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 4 weeks and then every 3&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>November 2009</start_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum-tolerated dose (MTD) and recommended dose (RD)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rates and toxicity at MTD and RD</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate according to RECIST criteria</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression according to RECIST criteria</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response or disease stabilization according to RECIST criteria</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival according to RECIST criteria</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of the combination regimen on drug pharmacokinetics</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life evaluated by EQ-5D (Euro QoL)</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Cisplatin, Etoposide &amp; Panobinostat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <arm_group_label>Cisplatin, Etoposide &amp; Panobinostat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide phosphate</intervention_name>
    <arm_group_label>Cisplatin, Etoposide &amp; Panobinostat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>panobinostat</intervention_name>
    <arm_group_label>Cisplatin, Etoposide &amp; Panobinostat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <arm_group_label>Cisplatin, Etoposide &amp; Panobinostat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <arm_group_label>Cisplatin, Etoposide &amp; Panobinostat</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed small cell lung cancer&#xD;
&#xD;
               -  Extensive-stage disease&#xD;
&#xD;
          -  Measurable disease according to RECIST criteria&#xD;
&#xD;
          -  No symptomatic brain metastasis or meningeal tumors&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Life expectancy ≥ 6 months&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 10.0 g/dL&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 x upper limit of normal (ULN) OR 24-hour creatinine clearance ≥&#xD;
             to 60 mL/min&#xD;
&#xD;
          -  Magnesium, potassium, and phosphorus ≥ the lower limit of normal OR correctable with&#xD;
             supplements prior to study treatment&#xD;
&#xD;
          -  AST/ALT ≤ 2.5 x ULN (≤ 5.0 x ULN if hepatic metastases are present)&#xD;
&#xD;
          -  Serum bilirubin ≤ 1.5 x ULN&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 x ULN OR liver fraction ≤ 2.5 x ULN&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective double contraception (at least 1 barrier method)&#xD;
             during and for at least 30 days after completion of study treatment&#xD;
&#xD;
          -  No impaired cardiac function, including any one of the following:&#xD;
&#xD;
               -  LVEF &lt; 45% as determined by ECHO&#xD;
&#xD;
               -  Complete left bundle branch block, obligate use of a cardiac pacemaker,&#xD;
                  congenital long QT syndrome, history or presence of atrial or ventricular&#xD;
                  tachyarrhythmias, clinically significant resting bradycardia (&lt; 50 beats per&#xD;
                  minute), QTcF &gt; 480 msec on screening ECG, or right bundle branch block and left&#xD;
                  anterior hemiblock (bifascicular block)&#xD;
&#xD;
               -  Uncontrolled angina pectoris or acute myocardial infarction within the past 3&#xD;
                  months&#xD;
&#xD;
               -  Other clinically significant heart disease (e.g., congestive heart failure,&#xD;
                  uncontrolled hypertension, history of labile hypertension, or history of poor&#xD;
                  compliance with an antihypertensive regimen)&#xD;
&#xD;
          -  No history of HIV or AIDS-related illness&#xD;
&#xD;
          -  No acute or chronic liver or renal disease&#xD;
&#xD;
          -  No other concurrent severe and/or uncontrolled medical conditions that could cause&#xD;
             unacceptable safety risks or compromise compliance with the protocol, including any of&#xD;
             the following:&#xD;
&#xD;
               -  Uncontrolled diabetes&#xD;
&#xD;
               -  Chronic obstructive or chronic restrictive pulmonary disease&#xD;
&#xD;
               -  Active or uncontrolled infection&#xD;
&#xD;
          -  No known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs&#xD;
             chemically related to panobinostat, cisplatin, or etoposide&#xD;
&#xD;
          -  No hearing impairment that would be a contraindication to the use of cisplatin&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
          -  No investigational drug or experimental medications or treatments within the past 30&#xD;
             days or 5 half-lives, whichever is longer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Donnellan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Galway University Hospital</affiliation>
  </overall_official>
  <removed_countries>
    <country>Ireland</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>July 9, 2010</study_first_submitted>
  <study_first_submitted_qc>July 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2010</study_first_posted>
  <last_update_submitted>December 30, 2014</last_update_submitted>
  <last_update_submitted_qc>December 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 31, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>extensive stage small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Panobinostat</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

